A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Hiv-Associated Chronic Inflammation.
Adenosine is a potent immunoregulatory nucleoside produced during inflammatory states to limit tissue damage. We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic HIV-1 associated inflammation. Virally-suppressed participants on antiretroviral therapy were randomized 1:1 for 12 weeks of dipyridamole 100mg 4x/day vs placebo capsules. All participants took open-label dipyridamole during weeks 12 to 24. Study endpoints included changes in systemic inflammation [soluble (s) CD163, sCD14, and interleukin-6] and levels of T cell immune activation (HLA-DR+CD38+). Forty participants were randomized: 17 dipyridamole and 18 placebo recipients had baseline and week 12 data available for analyses. There were no significant changes in soluble markers apart from a trend towards decreased sCD163 levels (p=0.087). There was a modest decrease in CD8+ T cell activation (-17.53% vs 13.31% change; p=0.032), but the significance was lost in the pooled analyses (p=0.058). Dipyridamole also reduced CD4+ T cell activation (-11.11% change; p=0.006) in the pooled analyses. In post-hoc analysis, detectable plasma DP levels were associated with higher levels of inosine, an adenosine surrogate, and of cyclic adenosine monophosphate. Dipyridamole increased extracellular adenosine levels and decreased T cell activation significantly among persons with HIV-1 infection on virally-suppressive therapy.